drugset / Trial / NCT02147990
Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer
RandomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and anti-tumor effect of rociletinib. The trial is open-ended, which means patients will continue to take rociletinib until the study doctor determines it is no longer beneficial for them.
Timeline
- Start
- 2014-06-16
- Primary completion
- 2019-07-30
- Completion
- 2019-08-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rociletinib | Small molecule | 500 mg | Oral |
| Subject | Rociletinib | Small molecule | 625 mg | Oral |